EphA2: A promising therapeutic target in breast cancer

A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency

(2020) Ehsan Rezaie et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Role of EFNA1 in tumorigenesis and prospects for cancer therapy

(2020) Yongping Hao et al.   BIOMEDICINE & PHARMACOTHERAPY

Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains

(2020) Marina P. Gehring et al.   CELLULAR SIGNALLING

Targeting EphA2 in cancer

(2020) Ta Xiao et al.   Journal of Hematology & Oncology

ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2

(2019) Romain Lévêque et al.   CANCER LETTERS

Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)

(2019) Nune Markosyan et al.   JOURNAL OF CLINICAL INVESTIGATION

Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers

(2019) Daisong Wang et al.   CELL RESEARCH

Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast

(2019) Debarpan Mitra et al.   BREAST CANCER RESEARCH AND TREATMENT

Synergy between EphA2-ILs-DTXp, a novel EphA2 targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models

(2019) Walid S. Kamoun et al.   MOLECULAR CANCER THERAPEUTICS

An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells

(2018) ATSUSHI SAKAMOTO et al.   ANTICANCER RESEARCH

YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells

(2018) Zhi Liu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate

(2018) Ahmed F. Salem et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer

(2018) Tao Zhang et al.   EBioMedicine

Caught in the “Akt”: Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF

(2018) Xiaojun Shi et al.   Science Signaling

Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux

(2018) Angie M. Torres-Adorno et al.   ONCOGENE

S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties

(2018) Jiao-Yang Li et al.   CANCER LETTERS

Protein C receptor stimulates multiple signaling pathways in breast cancer cells

(2017) Daisong Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Breast cancer: T-DM1 — an important agent in the history of breast cancer management

(2017) Otto Metzger-Filho et al.   Nature Reviews Clinical Oncology

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers

(2017) W Song et al.   ONCOGENE

Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer

(2017) Naohiko Koshikawa et al.   Cell Death & Disease

Novel anti-EPHA2 antibody, DS-8895a for cancer treatment

(2016) Jun Hasegawa et al.   CANCER BIOLOGY & THERAPY

The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer

(2016) Victoria M. Youngblood et al.   CANCER RESEARCH

The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?

(2016) Flavia Mercurio et al.   CURRENT MEDICINAL CHEMISTRY

Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a

(2016) I. J. G. Burvenich et al.   JOURNAL OF NUCLEAR MEDICINE

miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of theEPHA2oncogene

(2015) Efrosini Tsouko et al.   CARCINOGENESIS

Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers

(2015) Zhaoming Guo et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling

(2015) Deo R. Singh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2

(2015) Yue Zhou et al.   Nature Communications

Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors

(2015) Elizabeth M. Bruckheimer et al.   NEOPLASIA

Role of plasma membrane lipid composition on cellular homeostasis: learning from cell line models expressing fatty acid desaturases

(2014) M. S. Jaureguiberry et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

JNK Signaling Mediates EPHA2-Dependent Tumor Cell Proliferation, Motility, and Cancer Stem Cell-like Properties in Non-Small Cell Lung Cancer

(2014) W. Song et al.   CANCER RESEARCH

EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties

(2014) H Miao et al.   ONCOGENE

A novel human Fab antibody for Trop2 inhibits breast cancer growthin vitroandin vivo

(2013) Hong Lin et al.   INTERNATIONAL JOURNAL OF CANCER

Chemical–Physical Changes in Cell Membrane Microdomains of Breast Cancer Cells After Omega-3 PUFA Incorporation

(2012) Paola A. Corsetto et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma

(2012) Kevin KH Chow et al.   MOLECULAR THERAPY

A Small Molecule Agonist of EphA2 Receptor Tyrosine Kinase Inhibits Tumor Cell Migration In Vitro and Prostate Cancer Metastasis In Vivo

(2012) Aaron Petty et al.   PLoS One

Pro-nerve Growth Factor Induces Autocrine Stimulation of Breast Cancer Cell Invasion through Tropomyosin-related Kinase A (TrkA) and Sortilin Protein

(2011) Yohann Demont et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Eph/Ephrin Profiling in Human Breast Cancer Reveals Significant Associations between Expression Level and Clinical Outcome

(2011) Dana M. Brantley-Sieders et al.   PLoS One

Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer

(2010) Yesim Gökmen-Polar et al.   BREAST CANCER RESEARCH AND TREATMENT

EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt

(2009) Hui Miao et al.   CANCER CELL

Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy

(2009) G. Zhuang et al.   CANCER RESEARCH

Regulation of Mammary Gland Branching Morphogenesis by EphA2 Receptor Tyrosine Kinase

(2009) David Vaught et al.   MOLECULAR BIOLOGY OF THE CELL

EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells

(2009) B P Fox et al.   ONCOGENE

Identification and Functional Analysis of Phosphorylated Tyrosine Residues within EphA2 Receptor Tyrosine Kinase

(2008) Wei Bin Fang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling

(2008) Dana M. Brantley-Sieders et al.   JOURNAL OF CLINICAL INVESTIGATION

The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting

(2008) J. Wykosky et al.   MOLECULAR CANCER RESEARCH